Atom Investors’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Atom Investors’s Portfolio ITCI Stock Details ITCI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-9,309	Closed	-$777K	–	663
2024 Q4	$777K	Buy	+9,309	New	+$765K	0.1%	275
2024 Q1	–	Sell	-4,944	Closed	-$354K	–	689
2023 Q4	$354K	Sell	4,944 -71	-1%	-$4.08K	0.06%	335
2023 Q3	$261K	Buy	5,015 +898	+22%	+$52.3K	0.06%	337
2023 Q2	$261K	Buy	+4,117	New	+$257K	0.1%	206
2022 Q4	–	Sell	-21,021	Closed	-$978K	–	341
2022 Q3	$978K	Sell	21,021 -10,404	-33%	-$543K	0.34%	90
2022 Q2	$1.79M	Sell	31,425 -2,835	-8%	-$161K	0.78%	33
2022 Q1	$2.1M	Buy	34,260 +6,707	+24%	+$348K	0.98%	17
2021 Q4	$1.44M	Buy	+27,553	New	+$1.16M	0.24%	77
2020 Q3	–	Sell	-116,579	Closed	-$2.99M	–	644
2020 Q2	$2.99M	Sell	116,579 -34,660	-23%	-$702K	0.19%	101
2020 Q1	$2.33M	Buy	+151,239	New	+$3.28M	0.2%	104

Other funds holding ITCI

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return

HBK Investments Dallas, Texas $10.3B AUM 67.69% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

DKCM

Davidson Kempner Capital Management New York $8.42B AUM 61.81% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.76B AUM 62.41% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Atom Investors's ITCI Position: Q1 2025 in Review

Atom Investors sold out of Intra-Cellular Therapies Inc. (ITCI) in Q1 2025, closing a stake of 9,309 shares — an estimated $777K sold.

Atom Investors first reported a position in ITCI in Q1 2020 and held it in 10 quarters. The position peaked at $2.99M in Q2 2020. 395 funds tracked by Wall St. Rank hold ITCI as of Q1 2025.

Atom Investors reported no remaining Intra-Cellular Therapies Inc. position as of Q1 2025 after selling out during the quarter.
Atom Investors sold 9,309 Intra-Cellular Therapies Inc. shares in Q1 2025, an estimated $777K.
Atom Investors first reported a position in Intra-Cellular Therapies Inc. in Q1 2020 and held it in 10 quarters.
Atom Investors's Intra-Cellular Therapies Inc. position peaked at $2.99M in Q2 2020.
395 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q1 2025.

Based on Atom Investors's 13F filing for Q1 2025, filed 15 May 2025.